<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01221909</url>
  </required_header>
  <id_info>
    <org_study_id>EMC-DCR-TA</org_study_id>
    <nct_id>NCT01221909</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid in Dacryocystorhinostomy</brief_title>
  <acronym>TA-DCR</acronym>
  <official_title>Single Dose Tranexamic Acid for Dacryocystorhinostomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HaEmek Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HaEmek Medical Center, Israel</source>
  <brief_summary>
    <textblock>
      Single dose tranexamic acid (TA) before dacryocystorhinostomy (DCR) operation: a prospective,
      double blind, placebo controlled study.

      The study hypothesis: TA in DCR might reduce the intraoperative and postoperative bleeding in
      DCR surgery, and might reduce the duration of the surgery.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of DCR surgery in minutes and amount of blood loss in milliliters during surgery.</measure>
    <time_frame>Blood loss will be measured at the end of DCR operation from the suction bowel. Duration of surgery will be caculated by registering time of operation start and end.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late onset postoperative epistaxis or periorbital hematoma</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Nasolacrimal Tract Obstruction</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid single dose of 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>Single dose TA 500mg or placebo will be given in DCR surgery right after the first surgical incision.</description>
    <arm_group_label>Tranexamic acid single dose of 500mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline solution</intervention_name>
    <description>5cc saline solution</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  obstruction of nasolacrimal pathway

          -  eligible for DCR surgery

          -  18 years of age or older

        Exclusion Criteria:

          -  warfarin treatment

          -  renal insufficiency

          -  pregnancy

          -  mental retardation

          -  tendency to bleed

          -  thromboembolic disease

          -  thrombophilia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Haneen Jabaly-Habib, M.D.</last_name>
    <phone>972-506268059</phone>
    <email>hjabaly@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abed Mukari, M.D.</last_name>
    <phone>972-546881532</phone>
    <email>amukari@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of Ophthalmology, HaEmek medical center</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haneen Jabaly-Habib, M.D.</last_name>
      <phone>972-506268059</phone>
      <email>hjabaly@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Abed Mukari, M.D.</last_name>
      <phone>972-546881532</phone>
      <email>amukari@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Haneen Jabaly-Habib, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abed Mukari, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Briscoe, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>Ralley FE, Berta D, Binns V, Howard J, Naudie DD. One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty. Clin Orthop Relat Res. 2010 Jul;468(7):1905-11. doi: 10.1007/s11999-009-1217-8. Epub 2010 Jan 9. Erratum in: Clin Orthop Relat Res. 2010 May;468(5):1447.</citation>
    <PMID>20063079</PMID>
  </results_reference>
  <results_reference>
    <citation>Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs. 2003;63(13):1417-33. Review.</citation>
    <PMID>12825966</PMID>
  </results_reference>
  <results_reference>
    <citation>Astedt B. Clinical pharmacology of tranexamic acid. Scand J Gastroenterol Suppl. 1987;137:22-5. Review.</citation>
    <PMID>3321402</PMID>
  </results_reference>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2010</study_first_posted>
  <last_update_submitted>October 14, 2010</last_update_submitted>
  <last_update_submitted_qc>October 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Daniel Briscoe, M.D.</name_title>
    <organization>Chairperson of Ophthalmology Dept, EMC, Afula 18101, Israel</organization>
  </responsible_party>
  <keyword>bleeding</keyword>
  <keyword>dacryocystorhinostomy</keyword>
  <keyword>operative duration</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

